The global cardiac biomarkers market size reached US$ 10.7 billion in 2023. The market is projected to reach US$ 21.0 billion by 2032, exhibiting a growth rate (CAGR) of 7.8% during 2023-2032.
Cardiac markers, also known as cardiac biomarkers, are released into the bloodstream when the heart is stressed, or its muscles are damaged. These markers include different types of enzymes, hormones, and proteins, such as cardiac troponins, creatine kinase (CK), ischemia-modified albumin (IMA), and myoglobin. Measurement and testing of these markers can help in diagnosing heart conditions like cardiac ischemia and acute coronary syndrome (ACS). At present, the triage and diagnostic systems used for determining the risk of these conditions are based on electrocardiograms (ECGs) and clinical history. However, these systems are insufficient and can lead to misdiagnosis or delay in treatment. As cardiac marker testing offers higher accuracy and can identify the conditions in the early stages of presentation, they are gaining traction across the globe. These markers can also help in monitoring the prognosis of these condition with greater accuracy and providing the most effective treatment to the patients.
2. What is the expected growth rate of the global cardiac biomarkers market during 2024-2032?
3. What are the key factors driving the global cardiac biomarkers market?
4. What has been the impact of COVID-19 on the global cardiac biomarkers market?
5. What is the breakup of the global cardiac biomarkers market based on the location of testing?
6. What is the breakup of the global cardiac biomarkers market based on the application?
7. What are the key regions in the global cardiac biomarkers market?
8. Who are the key companies/players in the global cardiac biomarkers market?
Cardiac markers, also known as cardiac biomarkers, are released into the bloodstream when the heart is stressed, or its muscles are damaged. These markers include different types of enzymes, hormones, and proteins, such as cardiac troponins, creatine kinase (CK), ischemia-modified albumin (IMA), and myoglobin. Measurement and testing of these markers can help in diagnosing heart conditions like cardiac ischemia and acute coronary syndrome (ACS). At present, the triage and diagnostic systems used for determining the risk of these conditions are based on electrocardiograms (ECGs) and clinical history. However, these systems are insufficient and can lead to misdiagnosis or delay in treatment. As cardiac marker testing offers higher accuracy and can identify the conditions in the early stages of presentation, they are gaining traction across the globe. These markers can also help in monitoring the prognosis of these condition with greater accuracy and providing the most effective treatment to the patients.
Global Cardiac Biomarkers Market Drivers
Over the past few years, there has been a rise in the number of patients suffering from ACS which has created a demand for cardiac marker testing at a global level. Other than this, rising awareness among patients and healthcare providers about the importance of early diagnosis of various CVDs is driving the demand for these markers. In addition, there are numerous private and public organizations which are investing in R&D activities to develop advanced technologies in the field of cardiac biomarkers. For instance, blood tests for high-sensitivity cardiac troponin I have been demonstrated to identify patients who are at a higher risk of a second heart attack. Moreover, high accuracy and rapid results offered by biomarker testing, coupled with the availability of affordable cardiac point-of-care testing, are some of the other factors which are contributing to the growth of the market.Key Market Segmentation:
The report provides an analysis of the key trends in each sub-segment of the global cardiac biomarkers market report, along with forecasts at the global and regional level from 2023-2032. The report has categorized the market based on type, location of testing, and application.Breakup by Type:
- Troponins (T and I)
- Myocardial Muscle Creatine Kinase (CK-MB)
- Myoglobin
- Brain Natriuretic Peptide (BNPs) or NT-proBNP
- Ischemia Modified Albumin (IMA)
- Others
Breakup by Location of Testing:
- Laboratory Testing
- Point of Care Testing
Breakup by Application:
- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Atherosclerosis
- Others
Regional Insights:
- North America
- Asia-Pacific
- Europe
- Middle East and Africa
- Latin America
Competitive Landscape
The report has also analyzed the competitive landscape of the market with some of the key players being Abbott Laboratories, Alere Inc., Beckman Coulter, Becton, Dickinson And Co., Biomerieux, Bio-Rad Laboratories, Randox Laboratories, Roche Diagnostics Corporation, Siemens Healthcare and Thermo Fisher Scientific.Key Questions Answered in This Report
1. What was the size of the global cardiac biomarkers market in 2023?2. What is the expected growth rate of the global cardiac biomarkers market during 2024-2032?
3. What are the key factors driving the global cardiac biomarkers market?
4. What has been the impact of COVID-19 on the global cardiac biomarkers market?
5. What is the breakup of the global cardiac biomarkers market based on the location of testing?
6. What is the breakup of the global cardiac biomarkers market based on the application?
7. What are the key regions in the global cardiac biomarkers market?
8. Who are the key companies/players in the global cardiac biomarkers market?
Table of Contents
1 Preface3 Executive Summary11 Global Cardiac Biomarkers Industry: Value Chain Analysis13 Global Cardiac Biomarkers Industry: Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Cardiac Biomarkers Market
6 Market Breakup by Type
7 Market Breakup by Location of Testing
8 Market Breakup by Application
9 Market Breakup by Region
10 Global Cardiac Biomarkers Industry: SWOT Analysis
12 Global Cardiac Biomarkers Industry: Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Alere Inc.
- Beckman Coulter
- Becton
- Dickinson And Co. Biomerieux
- Bio-Rad Laboratories
- Randox Laboratories
- Roche Diagnostics Corporation
- Siemens Healthcare and Thermo Fisher Scientific
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 141 |
| Published | January 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 10.7 Billion |
| Forecasted Market Value ( USD | $ 21 Billion |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
